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In 2004 and 2005, 5 metallo-β-lactamase (MBL)-posi-
tive  Acinetobacter baumannii isolates were found in 2
Greek hospitals. Isolates were unrelated and carried
blaVIM-1 in a class 1 integron; blaOXA-51- and  blaOXA-58-like
carbapenemase genes were also detected. VIM-1 MBL in
Acinetobacter spp. causes concern, given the increasing
resistance of this species.
I
n the last few years, resistance to antibacterial drugs has
been increasing in Acinetobacter spp., which will likely
become a substantial treatment challenge in the future (1).
Carbapenems have potent activity against Acinetobacter
spp. and are usually the drugs of choice against multidrug-
resistant Acinetobacter baumannii isolates. Acinetobacter
spp. may develop resistance to carbapenems through vari-
ous mechanisms, including class B and D carbapenemase
production, decreased permeability, altered penicillin-
binding proteins, and rarely, overexpression of efflux
pumps (2,3).
In Europe, carbapenem resistance in A. baumannii has
been sporadically attributed to the production of IMP-type
metallo-β-lactamases (MBLs) and OXA-type carbapene-
mases (4). VIM-2–producing Acinetobacter spp. have
been isolated in the Far East (4,5) and on 1 occasion in
Germany (6). In this study, we report the appearance of the
VIM-1 MBL determinant among A. baumannii in Greece.
The Study
We included in the study A. baumannii clinical isolates
from tertiary care hospitals in 2 different Greek regions
(Hippokration University Hospital, Thessaloniki, and
University Hospital of Larissa, Thessalia) that were posi-
tive by the imipenem-EDTA double-disk synergy test
(DDST) from March 2004 to March 2005. Bacteria were
provisionally identified to the genus level by the Vitek 2
automated system (bioMérieux, Marcy l’ Étoile, France)
and the ATB 32GN system (bioMérieux). Antimicrobial
drug susceptibility testing of the DDST-positive isolates
for β-lactams (aztreonam, ceftazidime, cefepime, imipen-
em, meropenem, and piperacillin), β-lactam/β-lactamase
inhibitor combinations (ampicillin/sulbactam, piperacillin/
tazobactam), aminoglycosides (amikacin, gentamicin,
netilmicin, and tobramycin), fluoroquinolones
(ciprofloxacin and ofloxacin), and colistin was performed
by Etest and Etest MBL(AB Biodisk, Solna, Sweden). The
Clinical and Laboratory Standards Institute (CLSI) inter-
pretative criteria were used (7), and Pseudomonas aerugi-
nosa ATCC 27853 was used as control.
Polymerase chain reaction (PCR) testing of the syner-
gy-positive isolates for carbapenemase genes was done by
using consensus primers for blaIMP (8), blaVIM (9), blaSPM
(10), blaOXA-23-like (11), blaOXA-24-like (11), blaOXA-58-like (11),
and  blaOXA-51-like (12). Pulsed-field gel electrophoresis
(PFGE) of ApaI-digested genomic DNA was performed in
the  blaVIM-1-positive isolates, and the banding patterns
were compared by using criteria proposed by Tenover et al.
(13). The potential for conjugational transfer of imipenem
resistance was examined in filter matings by using
Escherichia coli 20R764 (lac+ rifr) as the recipient. Donor
and recipient were mixed in a 1:5 ratio, and transconju-
gants were selected on MacConkey agar plates containing
100 µg/mL rifampicin and imipenem at concentrations of
0.5 to 2 µg/mL or 2 µg/mL ceftazidime.
Five A. baumannii clinical isolates that were MBL pro-
ducers on the basis of DDST were detected among collec-
tions of isolates from patients hospitalized during the study
period. Two of the isolates were recovered from blood cul-
tures, 1 from bronchial secretions, 1 from a urine speci-
men, and 1 from cerebrospinal fluid; 2 isolates that had
reduced susceptibility to carbapenems were not positive by
the Etest MBL (Table). Imipenem MICs ranged from 4 to
>32 µg/mL, while meropenem MICs were 2–32 µg/mL.
P. aeruginosaATCC 27853 was consistently characterized
as having imipenem MIC of 2 µg/mL and meropenem
MIC of 0.5 µg/mL. The 5 A. baumannii isolates were mul-
tidrug resistant; they showed resistance to all other antimi-
crobial drugs tested, with the exception of colistin.
We did not detect blaIMP,  blaSPM,  blaOXA-23-like, or
blaOXA-24-like in any of the 5 isolates, whereas blaVIM was
detected in all of them. In 2 isolates, blaOXA-51- and blaOXA-
58-like genes were also simultaneously present, while 2 more
carried a blaOXA-51-like gene (Table). By sequencing both
strands of the entire blaVIM amplicons (14), a blaVIM-1
sequence identical to that available in the database was
identified. Sequencing blaOXA-51-like amplicons identified
blaOXA-66 in all cases, while blaOXA-58-like alleles were clas-
sical blaOXA-58 in both cases. In 2 isolates, 1 from each
region, PCR mapping of the integron that possibly carried
blaVIM-1, with primers 5′ CS and a set of primers for genes
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gron with a variable region including from 5′ to 3′ blaVIM-1,
aacA7, dhfrI, and aadA1 gene cassettes. Sequencing of the
overlapping PCR amplicons showed that this class 1 inte-
gron contained the intI1 gene with a strong P1 promoter,
an inactivated (without a GGG insertion) P2 promoter, an
attI1 site, and the blaVIM-1 gene cassette with its 59-base
element identical to those reported previously in other
gram-negative bacteria from Greece (15). PFGE showed
that the 5 blaVIM-1-positive isolates did not form a geneti-
cally homogeneous group; they belonged to 4 distinct
types. The 2 isolates from Thessaloniki were subtypes of
the same clone (Table, Figure). In none of the 5 isolates
was blaVIM-1 transferable to the susceptible E. coli host
after repeated conjugal experiments with imipenem or cef-
tazidime selection. The 5,387-bp nucleotide sequence of
the integron structure reported in this study has been sub-
mitted to the EMBL/GenBank/DDBJ sequence databases
and has been assigned accession no. DQ112355.
Conclusions
This is the first report of the VIM-1 determinant in A.
baumannii in the world. Occurrence of VIM-2 MBL
among A. baumannii and Acinetobacter genomospecies 3
isolates has previously been described among clinical iso-
lates in Korea (4,5). In Europe, IMP-type enzymes had
been reported in single A. baumannii isolates from some
European regions (4) and VIM-2 from 1 German hospital
(6), while MBLs have not been detected in A. baumannii
from the United States despite carbapenem resistance there
(1). Though anticipated because of the circulation of
blaVIM genes in several other gram-negative species in
Europe and the ability of Acinetobacter spp. to acquire for-
eign DNA, this evolution is worrisome.
Retention of moderate susceptibility to carbapenems by
blaVIM-positive  A. baumannii isolates in our study may
seem unexpected, since MBLs hydrolyze these com-
pounds. However, MBL production in gram-negative bac-
teria may not substantially increase carbapenem MICs
without the simultaneous operation of other mechanisms,
such as impaired permeability (2,4). Furthermore, 2 of the
4 strains carrying oxacillinase genes with carbapenemase
properties had imipenem MICs not higher than the CLSI
breakpoints for resistance. Recently, blaOXA-51-like genes
have been shown to be possibly naturally occurring (12),
while OXA-58 enzymes play a minor role in carbapenem
resistance in A. baumannii, and strong promoter sequences
are needed for higher levels of resistance to carbapenems
(2).
During the last few years, A. baumannii has been
increasingly isolated from severely ill patients, and its
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Figure. Pulsed-field gel electrophoresis of ApaI-restricted genom-
ic DNA of the 5 blaVIM-1-positive Acinetobacter baumannii isolates.
The index numbers of the isolates are those listed in the Table.
Lane M, molecular mass marker (48.5 kb).usual cross-resistance to most available antimicrobial
drugs, including carbapenems, poses substantial problems
worldwide and especially in the United States (1). In New
York, approximately two thirds of isolates are carbapenem
resistant (3). In our region, Acinetobacter spp. are frequent
nosocomial pathogens and are commonly multidrug resist-
ant, which leads to the extensive use of carbapenems and,
lately, polymyxins. The presence of MBLs among car-
bapenem-resistant Acinetobacter spp. from different Greek
regions emphasizes the need for restricted use of carbapen-
ems and early recognition of strains producing these
enzymes. Although Etest MBLwas reliable to detect VIM-
2-producing  Acinetobacter spp. in Korea (5), the assay
seems unable to identify MBL-positive isolates exhibiting
relatively low carbapenem MICs. Therefore, our diagnos-
tic laboratories should screen Acinetobacter spp. with
imipenem-EDTA DDST or alternative DDSTs, such as
those using 2-mercaptopropionic acid, which appears to be
more sensitive for detecting MBLs among Acinetobacter
spp. (4). Whether carbapenems might be appropriate to
treat infections with low-level carbapenem-resistant or
susceptible blaVIM-bearing A. baumannii isolates has yet to
be determined.
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